Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7A6R5)

Drug Name

SCH-900117 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-17 (IL17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brodalumab	DMASDQ6	Plaque psoriasis	EA90.0	Approved	[3]
Bimekizumab	DMR9TF1	Plaque psoriasis	EA90.0	Approved	[4]
Ixekizumab	DMXW92T	Plaque psoriasis	EA90.0	Approved	[5]
CNTO-6785	DM6RQXB	Rheumatoid arthritis	FA20	Phase 2	[6]
ABT-122	DM23UQ9	Psoriatic arthritis	FA21	Phase 2	[7]
CJM112	DMTSVJM	Acne vulgaris	ED80	Phase 2	[8]
COVA322	DM824EG	Psoriasis vulgaris	EA90	Phase 1/2a	[9]
SHR-1314	DMADNY3	Plaque psoriasis	EA90.0	Phase 1/2	[4]
ABBV-257	DMCZI8L	Rheumatoid arthritis	FA20	Phase 1	[10]
ALX-0761	DMJ8ACF	Psoriasis vulgaris	EA90	Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029914)
2	Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
6	Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2.
7	DOI: 10.1136/annrheumdis-2015-eular.4042
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)